Tablets & capsules, liquid-dosage forms. Inhalables & intranasals. Injectables: intravenous, intramuscular & subcutaneous. Nanotechnology, dissolvable films and tablets & radio frequency transdermal drug delivery.
|
June 2, 2013
By:
Adeline Siew, PhD, Patricia Van Arnum
Pharmaceutical Technology
A multifaceted approach is needed to resolve the myriad of challenges in developing oral formulations of poorly soluble drugs.
|
|
May 2, 2013
By:
Aikaterini Lalatsa, PhD
Pharmaceutical Technology
The impact of new delivery technologies in designing peptide therapies.
|
|
May 1, 2013
By:
Kingman Ng, Ronald Malone, Changyun Xiong, Xuefeng Yi
Pharmaceutical Technology
The authors describe a holistic and integrated approach to focus on the linkage of the prefilled syringe with the four phases of product design, development, operation, and control.
|
|
May 1, 2013
By:
Patricia Van Arnum
Pharmaceutical Technology
Parenteral drug delivery offers a variety of challenges but also opportunities. The author examines recent developments in nanotechnology-based drug delivery and other advances in injection-based drug delivery.
|
May 1, 2013
Pharmaceutical Technology
Researchers recently developed a drug-delivery system to mitigate problems associated with jet-injection drug delivery, and also improved on the design and operation of microscale actuators as a possible drug-delivery method.
|
|
March 2, 2013
By:
Adeline Siew, PhD
Pharmaceutical Technology
Engineering nanoparticles with optimal properties for use in cancer therapies.
|
|
November 2, 2012
By:
Michael Lowenborg
Pharmaceutical Technology
Consider critical process parameters and strategies to optimize the manufacturing process.
|
October 22, 2012
By:
Stephanie Sutton
ePT--the Electronic Newsletter of Pharmaceutical Technology
Dr Reddy's is planning to acquire the specialty injectable company OctoPlus for approximately EUR 27.4 million ($35.7 million) in cash to strengthen its technological capabilities in drug delivery.
|
|
October 2, 2012
Pharmaceutical Technology
A Q&A with James Ingebrand, Vice President and General Manager of 3M Drug Delivery Systems Division, on recent industry trends.
|
|
